Celcuity Inc. (NASDAQ: CELC) announced positive results from the PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE